Karyopharm Therapeutics (NASDAQ:KPTI) Given New $5.00 Price Target at Robert W. Baird

Karyopharm Therapeutics (NASDAQ:KPTI) had its price objective lowered by stock analysts at Robert W. Baird from $8.00 to $5.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock.

Separately, HC Wainwright lowered their price objective on shares of Karyopharm Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, June 28th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $4.67.

Karyopharm Therapeutics Stock Down 3.4 %

Karyopharm Therapeutics stock traded down $0.03 during mid-day trading on Wednesday, hitting $0.81. The company’s stock had a trading volume of 316,062 shares, compared to its average volume of 1,498,580. The stock has a market capitalization of $101.10 million, a P/E ratio of -0.65 and a beta of 0.21. Karyopharm Therapeutics has a twelve month low of $0.62 and a twelve month high of $1.95. The stock’s fifty day moving average price is $0.94 and its two-hundred day moving average price is $1.12.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.01. The business had revenue of $33.13 million during the quarter, compared to analyst estimates of $35.02 million. Equities analysts expect that Karyopharm Therapeutics will post -1.16 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Deepika Pakianathan sold 360,744 shares of the business’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $1.00, for a total transaction of $360,744.00. Following the transaction, the director now directly owns 11,209 shares in the company, valued at approximately $11,209. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 1,275,473 shares of company stock worth $1,234,542. Corporate insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Karyopharm Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Bleakley Financial Group LLC purchased a new position in shares of Karyopharm Therapeutics during the 4th quarter valued at $33,000. Simplicity Solutions LLC purchased a new position in shares of Karyopharm Therapeutics during the 4th quarter valued at $33,000. Simplicity Wealth LLC acquired a new stake in shares of Karyopharm Therapeutics in the 1st quarter valued at $66,000. SG Americas Securities LLC lifted its stake in shares of Karyopharm Therapeutics by 295.0% in the 4th quarter. SG Americas Securities LLC now owns 73,430 shares of the company’s stock valued at $64,000 after purchasing an additional 54,839 shares during the last quarter. Finally, Monashee Investment Management LLC acquired a new stake in shares of Karyopharm Therapeutics in the 4th quarter valued at $115,000. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).